You are here

Article Text

Article menu
Download PDFPDF
Letters to JMG
Insulin-degrading enzyme is genetically associated with Alzheimer’s disease in the Finnish population
  1. Saila Vepsäläinen1,2,
  2. Michele Parkinson3,
  3. Seppo Helisalmi1,2,
  4. Arto Mannermaa4,
  5. Hilkka Soininen1,2,
  6. Rudolph E Tanzi3,
  7. Lars Bertram3,
  8. Mikko Hiltunen1,2,3
  1. 1Department of Neurology, University Hospital and University of Kuopio, Kuopio, Finland
  2. 2Brain Research Unit, Clinical Research Centre/Mediteknia, University of Kuopio, Kuopio, Finland
  3. 3Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, USA
  4. 4Department of Pathology, University Hospital of Kuopio, Kuopio, Finland
  1. Correspondence to:
 Mikko Hiltunen
 PhD, Department of Neuroscience and Neurology, Kuopio University, P.O. Box 1627, 70211 Kuopio, Finland; mikko.hiltunen{at}uku.fi

Abstract

The gene for insulin-degrading enzyme (IDE), which is located at chromosome 10q24, has been previously proposed as a candidate gene for late-onset Alzheimer’s disease (AD) based on its ability to degrade amyloid β-protein. Genotyping of single nucleotide polymorphisms (SNPs) in the IDE gene in Finnish patients with AD and controls revealed SNPs rs4646953 and rs4646955 to be associated with AD, conferring an approximately two-fold increased risk. Single locus findings were corroborated by the results obtained from haplotype analyses. This suggests that genetic alterations in or near the IDE gene may increase the risk for developing AD.

  • AD, Alzheimer’s disease
  • APOE, apolipoprotein E
  • IDE, insulin-degrading enzyme
  • LD, linkage disequilibrium
  • SNP, single nucleotide polymorphism
  • Alzheimer’s disease
  • insulin-degrading enzyme (IDE)
  • risk gene
  • single nucleotide polymorphism (SNP)

https://doi.org/10.1136/jmg.2006.048470

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None declared.

    • Ethics approval: The Ethics Committee of Kuopio University Hospital and Kuopio University approved the study.

    • Published Online First 11 May 2007